Projection Mapping Showcase of "YOASOBI / 'Idol’” Premiered Saturday, December 14!
20.1.2025 04:14:00 CET | Business Wire | Press release
~ Over 450,000 Visitors Have Experienced "TOKYO Night & Light" ~
The Tokyo Metropolitan Government has been hosting year-round projection mapping displays at the iconic Tokyo Metropolitan Government Building (No. 1 Building). These displays use light and sound to create vibrant and diverse works of art, transforming the landmark into a new tourism resource that illuminates Tokyo’s nightscape. The event began in February of 2024 and has been visited by approximately 450,000 people to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107191600/en/
YOASOBI / 'Idol’ (Photo: Business Wire)
Recently, a new projection mapping work featuring YOASOBI's globally acclaimed song "Idol" premiered on Saturday, December 14. The opening day saw a large number of visitors from both Japan and abroad, creating an exciting atmosphere befitting such a popular attraction.
Feedback from attendees included comments such as, "I came to Japan as a tourist, and after seeing the weekday version, I wanted to see the weekend version as well, so I came back," "This is the most powerful projection mapping I've ever seen -- it was truly moving," and "YOASOBI's new content had a retro vibe, which I really enjoyed. I don’t think you’d see something like this very often overseas.”
Visitors can enjoy projection mapping videos created by renowned domestic and international creators, who have been highly praised at international competitions. This event is quickly evolving into one of Tokyo's must-visit tourist attractions. With its exceptional artistry, cutting-edge technology, and world-class content, this "new nighttime tourism hotspot that lights up Tokyo's nights" is one to watch.
Overview of the Work | YOASOBI / "Idol"
The song "Idol" by YOASOBI, which gained widespread attention as the theme song for an anime, is a masterpiece that blends rhythmic and vibrant elements with themes of uncertainty and inner conflict. The projection mapping display brings the emotional nuances of this song to life, offering an immersive visual and auditory experience.
Creator: Yukihiro Oka (Japan)
* Please visit our website for the screening schedule.
https://tokyoprojectionmappingproject.jp/en/
About the song
YOASOBI’s hit song "Idol" broke records by surpassing 800 million cumulative streaming plays in the shortest time ever. It topped several major global charts, including the U.S. Billboard Global Chart “Global Excl. U.S.,” Apple Music’s “Top 100: Global,” and YouTube Music Charts TOP 100 Songs Global, setting unprecedented milestones in J-POP history.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107191600/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom